| Bioactivity | Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology. |
| Invitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. |
| Name | Thalidomide-O-amido-PEG2-C2-NH2 TFA |
| CAS | 1957235-75-4 |
| Formula | C23H27F3N4O10 |
| Molar Mass | 576.48 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. ARYL SULFONOHYDRAZIDES. WO 2017/176958 A1. |
Thalidomide-O-amido-PEG2-C2-NH2 TFA
CAS: 1957235-75-4 F: C23H27F3N4O10 W: 576.48
Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.